康妇炎胶囊联合头孢哌酮舒巴坦钠及吗啉硝唑治疗盆腔炎性疾病疗效

来源期刊：广州医药 | 29-33 发布时间：2023-05-18 收稿时间：2025/11/13 18:35:24 阅读量：22

作者：: 李月菊,

关键词：: 康妇炎胶囊头孢哌酮舒巴坦钠吗啉硝唑盆腔炎性疾病; Kangfuyan capsule cefoperazone sulbactam sodium morinidazole pelvic inflammatory disease

DOI：: 10.3969/j.issn.1000-8535.2023.04.005

收稿时间：: 2022-04-16
修订日期：
接收日期：
引用总数：: 2

目的为寻找治疗盆腔炎性疾病（PID）的有效治疗方案,对比分析头孢哌酮舒巴坦钠+吗啉硝唑、康妇炎胶囊联合头孢哌酮舒巴坦钠及吗啉硝唑两种用药方案治疗PID的效果差异,期望为今后临床中合理选择PID药物治疗方案提供参考依据。方法选取2019年1月—12月期间在我院接受治疗的104例急性PID患者（湿毒壅盛证）作为研究对象,用随机信封分为参照组、研究组,各52例。予以参照组患者头孢哌酮舒巴坦钠+吗啉硝唑静脉滴注治疗,研究组患者在参照组基础上口服康妇炎胶囊,均持续治疗14 d。观察2组患者近期疗效、炎性因子、盆腔炎性疾病包块、远期复发率（6个月、1年）、远期生活质量,综合评价两种用药方案应用效果。结果治疗14 d后,研究组总有效率96.00%,高于参照组的80.39%,差异显著（P<0.05）;WBC、CRP、IL-2、TNF-α四项炎性因子水平均低于参照组,差异显著（P<0.05）;腔包块直径、疼痛评分均低于参照组,差异显著（P<0.05）。随访6个月、1年,研究组患者PID复发率分别为4.00%、10.00%,均低于参照组的15.69%、29.41%,差异显著（P<0.05）。结论以康妇炎胶囊联合头孢哌酮舒巴坦钠及吗啉硝唑治疗PID,能够提升患者的近期治疗效果,改善炎性反应、盆腔炎性疾病包块,降低远期复发风险,改善远期生活质量,而且能够保证用药安全性,具有推广使用价值。

Objective To find an effective treatment for pelvic inflammatory disease（PID）,and to compare and analyze the difference of efficacy of cefoperazone and sulbactam sodium + molinidazole,Kangfuyan capsule combined with cefoperazone and sulbactam sodium + molinidazole in the treatment of PID,in order to provide reference for rational selection of PID drug treatment in future clinical practice．Methods A total of 104 patients with acute PID（excessive wet toxin accumulation syndrome）who received treatment in our hospital from January to December 2019 were selected as the research objects．They were randomly divided into the control group and the research group with 52 cases in each group．Patients in the control group were given intravenous infusion of cefoperazone and sulbactam sodium + morinidazole,and patients in the research group were given Kangfuyan capsule orally on the basis of the control group,all treated for 14 days．The short-term efficacy,inflammatory factors,pelvic inflammatory mass and pain improvement,adverse reactions,long-term recurrence rate（6 months,1 year）,long-term quality of life in two groups were observed,and the application effect of the two drug regimens was comprehensively evaluated．Results After 14 days of treatment,the total effective rate of the research group was 96.00%,which was higher than that of the control group（80.39%）,with significant difference（P<0.05）．After treatment,the levels of WBC,CRP,IL-2 and TNF-α were lower than those of the control group,and the differences were significant（P<0.05）．After treatment,lumen mass diameter and pain score were lower than the control group,the differences were significant（P<0.05）．After 6 months and 1 year follow-up,the PID recurrence rate of the research group was 4.00% and 10.00% respectively,both lower than that of the control group（15.69% and 29.41%）,with significant difference（P<0.05）．Conclusions Using Kangfuyan capsule combined with cefoperazone and sulbactam sodium + molinidazole in the treatment of PID,can improve the patient's recent treatment effect,improve the inflammatory reaction,pelvic inflammation mass, lower long-term risk of recurrence,improve the long-term quality of life,and can ensure medication safety,with promotion value.

1、袁英. 中西医三联药物方案治疗盆腔炎性疾病的效果较好[J].基因组学与应用生物学,2019,38(8):353-357.

2、杨妮,谢巍,肖萍.中医治疗盆腔炎性疾病的用药规律[J].广西医学,2019,41(1):13-16.

3、张学靖. 康妇炎胶囊联合头孢曲松钠及奥硝唑治疗慢性盆腔炎性疾病的疗效及对炎症因子水平的影响[J].首都食品与医药,2020,1(2):59-59.

4、邢艳红. 康妇炎胶囊联合头孢哌酮舒巴坦,奥硝唑治疗盆腔炎性疾病性疾病的效果[J].河南医学研究,2020,29(15):138-139.

5、王静云,李劼.吗啉硝唑治疗盆腔炎性疾病性疾病的临床疗效观察[J].医学临床研究,2012,29(12):2368-2369.

6、罗晓华,杨年,李忠勇,等.敏感抗生素联合康妇炎胶囊对慢性盆腔炎性疾病患者IL-1,IL-2,CRP,PCT水平的影响及疗效[J].国际病理科学与临床杂志,2020,40(5):1185-1191.

7、张瑞,廖星,谢雁鸣,等.《中医药单用/联合抗生素治疗盆腔炎性疾病性疾病临床实践指南》临床应用评价与修订意见[J].中国中药杂志,2018,43(24):4776-4781.

8、樊尚荣. 2015年美国疾病控制中心性传播疾病诊断和治疗指南更新内容和解读(续完)[J].中国全科医学,2015,18(30):3641-3643.

1、班海梅.康妇炎胶囊联合头孢噻肟钠治疗子宫内膜炎的疗效观察[J].中国医药指南,2023,21(30):143-145.DOI:10.15912/j.cnki.gocm.2023.30.039.

2、黄碗文,林智摸,余卓燊,等.仙方活命饮加减联合针刺对急性盆腔炎（湿热蕴结证）患者免疫功能和炎症状态的影响[J].中国中医急症,2023,32(12):2112-2115.